MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.

Abstract

BioMS Medical Corp, under license from the University of Alberta, is developing MBP-8298, a synthetic peptide analog of myelin basic protein, for the potential treatment of multiple sclerosis. Phase II and III clinical trials of MBP-8298 are underway.

• Authors: Cynthia Darlington
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 4 Pg. 398-402 (Aug 2007) ISSN: 1464-8431 [Print] England
• PMID: 17694453 (Publication Type: Journal Article)

Chemical References

• Myelin Basic Protein
• Peptide Fragments
• MBP-8298

Topics

• Animals
• Drug Design
• Humans
• Multiple Sclerosis (drug therapy)
• Myelin Basic Protein (chemical synthesis, chemistry, metabolism, therapeutic use)
• Patents as Topic
• Peptide Fragments (chemical synthesis, chemistry, metabolism, therapeutic use)
• Randomized Controlled Trials as Topic